首页> 美国卫生研究院文献>other >Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

【2h】

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

机译：一线表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变型非小细胞肺癌患者的淋巴细胞与单核细胞比率的基线和趋势作为预后因素

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundPatients with early-stage lung cancer who have a high baseline lymphocyte-to-monocyte ratio (LMR) have a favorable prognosis. However, the prognostic significance of LMR in patients with advanced-stage EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has not been established. We conducted a retrospective analysis to investigate the influence of LMR on clinical outcomes including progression-free survival (PFS) and overall survival (OS) in EGFR-mutant patients with NSCLC.

机译：背景基线淋巴细胞与单核细胞比率（LMR）高的早期肺癌患者的预后良好。然而，LMR在接受一线表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂（TKIs）的晚期EGFR突变非小细胞肺癌（NSCLC）患者中的预后意义尚未确定。我们进行了回顾性分析，以调查LMR对EGFR突变的NSCLC患者的临床结局包括无进展生存期（PFS）和总体生存期（OS）的影响。

著录项

期刊名称 other
作者
Yu-Mu Chen; Chien-Hao Lai; Huang-Chih Chang; Tung-Ying Chao; Chia-Cheng Tseng; Wen-Feng Fang; Chin-Chou Wang; Yu-Hsiu Chung; Yi-Hsi Wang; Mao-Chang Su; Kuo-Tung Huang; Hung-Chen Chen; Ya-Chun Chang; Meng-Chih Lin;
展开▼
作者单位

展开▼
年(卷),期 -1(10),8
年度 -1
页码 e0136252
总页数 13
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [J] . Chen Yu-Mu, Lai Chien-Hao, Chang Huang-Chih, Medicine. . 2015,第50期

机译：一线表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变型非小细胞肺癌患者的癌胚抗原的基线，趋势和正常化
2. Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [J] . Chen Yu-Mu, Lai Chien-Hao, Chang Huang-Chih, Medicine. . 2015,第50期

机译：一线表皮生长因子受体酪氨酸激酶抑制剂治疗的表皮生长因子受体突变型非小细胞肺癌患者的癌胚抗原的基线，趋势和正常化
3. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors [J] . Aguiar-Bujanda David, Duenas-Comino Arancha, Saura-Grau Salvador, Oncology research and treatment. . 2018,第12期

机译：嗜中性粒细胞与欧洲表皮生长因子受体 - 突变体非小细胞肺癌患者的预后因子作为酪氨酸激酶抑制剂治疗的预后因素
4. The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses Proliferation and Invasion of Human Oral Squamous Carcinoma Cells via p53 Independent and MMP, uPAR Dependent Mechanism [C] . EUN JU LEE, JIN HA WHANG, NAM KYEONG JEON, Meeting on Cell Signaling World: Signal Transduction Pathways as Therapeutic Targets . 2007

机译：表皮生长因子受体酪氨酸激酶抑制剂ZD1839（Iressa）通过独立于p53和MMP，uPAR依赖性机制抑制人口腔鳞状细胞癌细胞的增殖和侵袭
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Baseline Trend and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [O] . Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, -1

机译：一线表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变型非小细胞肺癌患者的癌胚抗原的基线趋势和正常化
7. Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. [O] . Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, 2015

机译：淋巴细胞与单核细胞比率的基线和趋势作为表皮生长因子受体突变非小细胞肺癌患者用一线表皮生长因子受体酪氨酸激酶抑制剂治疗的预后因素。

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

摘要

著录项

相似文献

相关主题

期刊订阅